SynthesisTheScientificWorldJournal2014
Efficacy and safety of acotiamide for the treatment of functional dyspepsia: systematic review and meta-analysis.
Synthesis in TheScientificWorldJournal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Second Asian Consensus Report on Functional Dyspepsia (2025): Updated Recommendations.Journal of gastroenterology and hepatology · 2026Pooled it
- Prokinetics for the treatment of functional dyspepsia: Bayesian network meta-analysis.BMC gastroenterology · 2017Pooled it
- A double-blind placebo controlled study of acotiamide hydrochloride for efficacy on gastrointestinal motility of patients with functional dyspepsia.Journal of gastroenterology · 2017Trial
- Efficacy of Acotiamide in Pediatric Patients with Functional Dyspepsia.Pediatric gastroenterology, hepatology & nutrition · 2025Article
- Review
- The Usefulness of Symptom-based Subtypes of Functional Dyspepsia for Predicting Underlying Pathophysiologic Mechanisms and Choosing Appropriate Therapeutic Agents.Journal of neurogastroenterology and motility · 2021Review
- Clinical Practice Guidelines for Functional Dyspepsia in Korea.Journal of neurogastroenterology and motility · 2020Review
- Application of Pyridostigmine in Pediatric Gastrointestinal Motility Disorders: A Case Series.Paediatric drugs · 2018Article
- The Diagnosis and Treatment of Functional Dyspepsia.Deutsches Arzteblatt international · 2018Article
- Prokinetics in the Management of Functional Gastrointestinal Disorders.Current gastroenterology reports · 2017Review
- Functional Dyspepsia: Advances in Diagnosis and Therapy.Gut and liver · 2017Review
- Effects of Electroacupuncture on Interstitial Cells of Cajal (ICC) Ultrastructure and Connexin 43 Protein Expression in the Gastrointestinal Tract of Functional Dyspepsia (FD) Rats.Medical science monitor : international medical journal of experimental and clinical research · 2016Article
- Profile of acotiamide in the treatment of functional dyspepsia.Clinical and experimental gastroenterology · 2016Review
- Women and functional dyspepsia.Women's health (London, England) · 2016Article
- Therapeutic strategies for functional dyspepsia and irritable bowel syndrome based on pathophysiology.Journal of gastroenterology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere are no treatments with established efficacy for this disorder so far.
aimTo systematically review the efficacy of acotiamide in the treatment of patients with FD.
methodsWe searched main electronic databases through November 2013. RCTs evaluating the efficacy of acotiamide versus placebo in FD patients were included. Pooled risk ratio (RR) with 95% confidential interval (CI) was calculated.
resultsSix publications including seven RCTs were eligible for inclusion. The summary RR of overall improvement of FD symptoms in patients receiving acotiamide versus placebo was 1.29 (95% CI, 1.19-1.40, P < 0.00001; I(2) = 15%). Acotiamide improved the symptoms of patients with postprandial distress syndrome (PDS) (RR, 1.29; 95% CI, 1.09-1.53, P = 0.003; I(2) = 0%), and the summary RR for patients with epigastric pain syndrome (EPS) was 0.92 (95% CI, 0.76-1.11, P = 0.39; I(2) = 0%). Acotiamide showed a significantly beneficial effect on the elimination of some individual FD symptoms compared with placebo. Adverse events were not significantly different between acotiamide and placebo groups. Subgroup analyses suggested that acotiamide 100 mg three times daily (tid) showed consistent efficacy not only for the overall improvement but also for the elimination of some individual symptoms in FD patients.
conclusionsAcotiamide has the potential to improve the symptoms of patients with FD, particularly of patients with PDS, without major adverse effects. The dosage of acotiamide 100 mg tid might be the appropriate dose in the treatment of FD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.